Small Molecule Inhibitors of Staphylococcus aureus RnpA Alter Cellular mRNA Turnover, Exhibit Antimicrobial Activity, and Attenuate Pathogenesis
2011

Small Molecule Inhibitors of Staphylococcus aureus RnpA Alter mRNA Turnover and Exhibit Antimicrobial Activity

publication 10 minutes Evidence: moderate

Author Information

Author(s): Patrick D. Olson, Lisa J. Kuechenmeister, Kelsi L. Anderson, Sonja Daily, Karen E. Beenken, Christelle M. Roux, Michelle L. Reniere, Tami L. Lewis, William J. Weiss, Mark Pulse, Phung Nguyen, Jerry W. Simecka, John M. Morrison, Khalid Sayood, Oluwatoyin A. Asojo, Mark S. Smeltzer, Eric P. Skaar, Paul M. Dunman

Primary Institution: University of Nebraska Medical Center

Hypothesis

RnpA is an essential target for antimicrobial drug discovery in Staphylococcus aureus.

Conclusion

The study identifies RnpA as a promising target for new antibiotics, demonstrating that its inhibition can reduce mRNA degradation and limit bacterial growth.

Supporting Evidence

  • RnpA is essential for Staphylococcus aureus survival and contributes to mRNA degradation.
  • Small molecule inhibitors of RnpA were identified that limit mRNA turnover.
  • RNPA1000 showed antimicrobial activity against various strains of Staphylococcus aureus.
  • RNPA1000 reduced bacterial burden in a mouse model of infection.
  • RnpA-inhibitory agents may represent a new class of antibiotics.

Takeaway

Scientists found a way to stop a bacteria called Staphylococcus aureus from growing by blocking a protein it needs, which could help create new medicines.

Methodology

The study used high-throughput screening to identify small molecule inhibitors of RnpA and assessed their effects on mRNA turnover and antimicrobial activity.

Limitations

The potential toxicity of the RnpA inhibitor RNPA1000 limits its direct use as a therapeutic agent.

Digital Object Identifier (DOI)

10.1371/journal.ppat.1001287

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication